ENDPOINTS NEWS15h
Drugs are ap­proved — and made avail­able — faster in US than most of EU, da­ta show
New drugs in the US were, on average, approved months before winning approval in the EU, according to new data from The IQVIA ...
ENDPOINTS NEWS19h
Gene edit­ing com­pa­nies seek safer, less gru­el­ing con­di­tion­ing meth­ods for blood stem cell ther­a­pies
Companies Beam Therapeutics and Prime Medicines presented research on reducing chemotherapy in gene therapy conditioning, ...
ENDPOINTS NEWS16h
NIH halts en­roll­ment in tri­al for SIGA's mpox an­tivi­ral af­ter dis­ap­point­ing da­ta
Another trial for SIGA Technologies' mpox antiviral has failed, and all enrollment has been stopped, the NIH's National ...
ENDPOINTS NEWS18h
Con­tend­ing with Amer­i­cans’ fury at health in­sur­ers
UnitedHealthcare CEO Brian Thompson's shooting death sparked public discussion about healthcare industry frustration. The ...
ENDPOINTS NEWS18h
Re­lay Ther­a­peu­tics plans piv­otal tri­al in sec­ond-line breast can­cer for 2025
Relay Therapeutics’ stock {$RLAY} rose about 6% on Wednesday morning after it released positive interim data for its PI3Kα ...
ENDPOINTS NEWS16h
Can­del’s shares soar on Phase 3 prostate can­cer da­ta de­spite un­clear prospects
Candel Therapeutics’ viral immunotherapy candidate passed a late-stage test in certain patients with prostate cancer, sending ...
ENDPOINTS NEWS20h
Eli Lil­ly has tapped tele­health start­up Ro to dis­trib­ute its sin­gle-dose Zep­bound vials
Through a new relationship with Eli Lilly, Ro patients can now get easier access to the drugmaker’s discounted, single-dose ...
ENDPOINTS NEWS19h
Ace­lyrin says good­bye to the drug that got it a $540M IPO in 2023
Ace­lyrin is of­fi­cial­ly end­ing de­vel­op­ment of an ex­per­i­men­tal med­i­cine it re­ferred to as a “ di­a­mond in the ...
ENDPOINTS NEWS22h
The End­points 100: The biotech in­dus­try braces for Trump 2.0
A survey of 77 biotech executives reveals concerns about FDA changes following Donald Trump's reelection. Martin Makary's ...
ENDPOINTS NEWS21h
Lil­ly’s oral SERD makes strides in breast can­cer with Phase 3 da­ta
Data from a Phase 3 study in second-line breast cancer showed that Eli Lilly’s oral SERD reduced the risk of progression or ...
ENDPOINTS NEWS22h
Ex­clu­sive: Negev Labs un­veils with $30M in as­sets, striv­ing to build a net­work of psy­che­del­ic biotechs
A new psychedelic-focused startup incubator is debuting, backed by an investor behind some of the most prominent biotechs in ...
ENDPOINTS NEWS22h
Bay­er ex­its Eu­rope pact with Moberg for nail fun­gus drug af­ter Phase 3 fail
Moberg Pharma's Terclara fails Phase 3 trial for fungal nail infection maintenance dosing; Bayer exits partnership and ...